Prostate-specific antigen screening in the United States vs in the European randomized study of screening for prostate cancer-Rotterdam

Journal of the National Cancer Institute

Volumn 102, Issue 5, 2010, Pages 352-355

  Wever, Elisabeth M ^a   Draisma, Gerrit ^a   Heijnsdijk, Eveline A M ^a   Roobol, Monique J ^a   Boer, Rob ^a   Otto, Suzie J ^a   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIMULATION; UNITED STATES;

AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); EUROPE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 77749297950     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp533     Document Type: Article

References (12)

1. Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specifc antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 1998;9(5):519-527.
2. Pinsky PF, Andriole GL, Kramer BS, et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol. 2005;173(3):746-750; discussion 750-751.
3. Andriole GL, Grubb RL III, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310- 1319.
4. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
5. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specifc antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95(12):868-878.
6. Draisma G, Postma R, Schroder FH, van der Kwast TH, de Koning HJ. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer. 2006;119(10): 2366-2371.
7. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classifcation of prostate cancer. Prostate Suppl. 1992;4:129-138.
8. Gleason DF. Classifcation of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3): 125-128.
9. Mariotto AB, Etzioni R, Krapcho M, Feuer EJ. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007;109(9): 1877-1886.
10. Grubb RL III, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on fndings from the initial four rounds of screening in a randomized trial. BJU Int. 2008;102(11):1524-1530.
11. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute; 2006. http://seer.cancer. gov/csr/1975-2003/ Accessed July 3, 2009.
12. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-spe-cifc antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101(6):374-383.